Memphasys Enters Revenue-Generating Phase After CE Mark for Felix IVF System

The latest update is out from Memphasys Ltd ( (AU:MEM) ).

Memphasys has entered a pivotal commercial phase following CE Mark approval for its Felix™ System, enabling routine sales across Europe and other CE-recognised markets and activating previously signed multi-year commercial agreements. In the December 2025 quarter, the company invoiced about $102,000 from Europe, the Middle East and Japan and secured approximately $1.5 million in contracted multi-year minimum revenues, including a five-year supply deal with Italy’s CFA Italia worth at least A$925,000 and first orders from Middle East partner ITL, which has already placed repeat cartridge orders. The regulatory milestone is designed to accelerate global expansion via mutual-recognition pathways in markets such as India and Australia, where the company has signed its first Indian supply agreement accessing more than 200 IVF clinics, while a 39% reduction in annual operating costs is intended to redirect capital toward manufacturing scale-up and regulatory progression to support its consumable-driven growth strategy.

The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.

More about Memphasys Ltd

Memphasys Ltd is an Australian biotechnology company focused on developing and commercialising innovative products for assisted reproduction, centering on its Felix™ sperm separation system for use in IVF clinics. The company targets global fertility markets, pursuing a consumables-led recurring revenue model and a go-direct sales strategy across Europe, the Middle East, Asia and other high-growth regions.

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$16.12M

For detailed information about MEM stock, go to TipRanks’ Stock Analysis page.